• Home
  • About Us
  • Blog

Pulmonary Hypertension RN

  • What is Pulmonary Hypertension?
    • What is Pulmonary Hypertension?
    • Pulmonary Hypertension Symptoms
    • Types of Pulmonary Hypertension
    • Causes of Pulmonary Hypertension
    • PH vs. PAH
    • Diastolic Heart Failure vs. PAH
    • WHO Group 3 Pulmonary Hypertension, IPF & COPD
    • Pulmonary Veno-Occlusive Disease
    • Hereditary Hemorrhagic Telangiectasia (HHT)
      • Hereditary Hemorrhagic Telangiectasia (HHT) Treatment
    • Functional Classification of Pulmonary Hypertension
    • Congenital Heart Disease
      • Eisenmenger’s Syndrome
      • Update on Management of PAH-CHD
      • Congenital Heart Disease & Sleep Apnea
      • Complex Congenital Heart Disease
      • Atrial Septal Defect and Pulmonary Arterial Hypertension
    • Pediatric Pulmonary Arterial Hypertension
    • Sickle Cell and Pulmonary Hypertension
    • Stimulant Associated Pulmonary Arterial Hypertension
    • Porto-Pulmonary Syndrome
    • Research, Life Expectancy & Prognosis for PH
  • Diagnosing & Monitoring PAH
    • Pulmonary Arterial Hypertension Diagnosis
    • How Am I Doing? Assessing Your PAH.
    • Blood Tests
    • Cardiopulmonary Exercise Test (CPET)
    • CT (Computed Tomography) Scan
    • Echocardiogram: An Overview
    • Echocardiogram: A Detailed Look
    • Pulmonary Function Tests (PFTs)
    • Right Heart Catheterization
    • Six Minute Walk
    • Ventilation Perfusion Scan (VQ Scan)
    • CTEPH
      • CTEPH: WHO Group 4 Pulmonary Hypertension
      • PTE (Pulmonary Thromboendarterectomy) Surgery
      • Adempas used to Treat PAH and CTEPH
  • PAH Treatment
    • Pulmonary Hypertension Centers
    • Pulmonary Hypertension Treatments
    • Continuously Infused Therapies Used to Treat PH
    • Prostanoids for Treatment of PH
    • Adcirca and Revatio Used to Treat Pulmonary Arterial Hypertension (PAH)
    • Adempas used to Treat PAH and CTEPH
    • Tracleer, Letairis, and Opsumit Treatments
    • Oxygen Therapy for Pulmonary Hypertension
    • Salt and Water Restrictions
    • Exercise & PAH
    • Diuretics
    • Blood Thinners
    • Getting the Most Out of PAH Therapy
      • Letairis
      • Opsumit
      • Sildenafil (Revatio)
  • Research
  • FAQ’s
    • Implanted Remodulin Pump, Right Heart Catheterization, PAH & Pregnancy
    • Oral Treatments, Care Centers & Hole in Heart
    • FAQ’s: Altitude, Cold & Allergy Medications
    • FAQ’s: Psoriasis, Idiopathic PAH, Contraceptives & PAH
    • FAQ’s: Causes of Pulmonary Hypertension, Symptom Frequency & Care Centers
    • FAQ: PAH Experts, Pregnancy, Mild PAH & Vacationing
    • FAQ’s: CTEPH, Blood Clots, Corrective Surgery & PAH Care Centers
    • FAQ’s: VQ Scans & PAH Curable?
    • FAQ’s: Mild Pulmonary Hypertension?
    • FAQ’s: Boating, Swimming & Eating with PAH
    • FAQ’s: Borderline Pulmonary Hypertension, Hand Swelling, Children with PAH, Costs

Pregnancy and Pulmonary Hypertension Part 1

March 18, 2014 By Dr. Jeremy Feldman

There are many challenges in caring for patients with PAH.  We ask our patients to take many different medications to help treat their disease process and we ask them to put up with side effects from these medications.  We ask our patients to change their lifestyles and eating habits.  One of the greatest challenges is the issue of pregnancy. PAH is particularly common in young women who might otherwise consider either starting a family or adding to their family.

Why is Pregnancy Harmful to a Woman with Pulmonary Arterial Hypertension?

Pulmonary hypertension and pregnancyUnderstanding the normal changes to a woman’s body that take place during pregnancy helps us understand why carrying a pregnancy can be so dangerous.  A woman’s body gradually retains salt and water during pregnancy such that by the end of the third trimester their blood volume has increased by 50%.  There is an increase in 6 to 8 liters of water and about 1000meq of sodium.  So if a woman had a total blood volume prior to pregnancy of 5 liters then at 36 weeks their blood volume would be 7.5 liters.  Heart rate increases by 15 to 20 beats per minute and cardiac output increases up to 50%. This dramatic increase in blood volume is accompanied by a mild anemia.  The anemia is well tolerated but in PAH the right ventricle is asked to work much harder.  In a woman without pulmonary hypertension the heart has no problem meeting the increased work load that is required but in PAH the added fluid can result in progressive right heart failure and death.

In addition to the extra work that is required of the right ventricle in pregnancy, several of the medications that are commonly used to treat pulmonary arterial hypertension are teratogenic (very harmful to the growing fetus).  Additional hurdles include the stress of delivery.  Normal labor requires a woman to push very vigorously to help the baby exit the birth canal.  This type of pushing can cause fainting and dangerously low blood pressure in a patient with PAH.  Many women choose to have a “spinal”.  This is an injection of medication to reduce the amount of pain and pressure experienced during the peak of labor.  In patients with pulmonary hypertension, this spinal injection can precipitate life-threateningly low blood pressure.  Cesarean section is sometimes required to safely deliver the baby.  Options for making this comfortable include spinal injection of anesthesia or general anesthesia (being put to sleep).  The latter can be very dangerous for PH patients even when performed by anesthesiologists expert in PAH management

Check back soon  for Part 2 of pregnancy and pulmonary hypertension.

Filed Under: Blog, Home Page, Living with PAH, Uncategorized

PAH Life Expectancy

PAH Research

Research, Life Expectancy & Prognosis for PH

Major Developments in Pulmonary Hypertension Affecting Prognosis 1.     Approval of

Where to Get Treatment?

CCCs for PAH

Pulmonary Hypertension Centers

Where to get treatment for pulmonary hypertension? Pulmonary arterial hypertension is a

Popular Posts

implantable remodulin pump system for pulmonary hypertension patients

Update on the Implantable System for Remodulin

By Dr. Jeremy Feldman

On December 22, 2017, after eight years of study, the FDA has finally granted pre-market approval (PMA) to the fully

PAH patient

Is My Prognosis Worse If I Have Failed Oral Pulmonary Hypertension Therapy?

By Dr. Jeremy Feldman

We recently received an interesting question from one of our readers.  “If oral therapy is not effective and in less

good news in pah

 

Disclaimer

Recent Blog Posts

  • In Memoriam:  Greg Ahearn, MD June 16, 2024
  • Sotatercept (Winrevair) Approved! June 1, 2024
  • Disappointing News for Rodatristat Ethyl October 11, 2023

Categories

Archives